Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Amanda R Patrick"'
Autor:
Pall Jonsson, Manuj Sharma, Seamus Kent, Ashley Jaksa, Liza Gibbs, Shaun Rowark, Stephen Duffield, Lynne Kincaid, Ayad K Ali, Amanda R Patrick, Priya Govil, Nicolle Gatto
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Objective To compare real-world effectiveness and safety of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke.Study design and setting A comparative cohort study in UK general practice
Externí odkaz:
https://doaj.org/article/7ade8453ce874eabbae04f690b92a445
Autor:
Ashley Jaksa, Lisa Bloudek, Josh J. Carlson, Kanya Shah, Yilin Chen, Amanda R. Patrick, Avery McKenna, Jon D. Campbell
Publikováno v:
International Journal of Technology Assessment in Health Care. 38
Health technology assessment (HTA) agencies are considering adopting a lifecycle approach to assessments to address uncertainties in the evidence base at launch and to revisit the clinical and economic value of therapies in a dynamic clinical landsca
Autor:
Ashley Jaksa, Liza Gibbs, Seamus Kent, Shaun Rowark, Stephen Duffield, Manuj Sharma, Lynne Kincaid, Ayad K Ali, Amanda R Patrick, Priya Govil, Pall Jonsson, Nicolle Gatto
Publikováno v:
BMJ Open. 12:e064662
ObjectiveTo compare real-world effectiveness and safety of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke.Study design and settingA comparative cohort study in UK general practice d
Autor:
William Murk, Amanda R. Patrick, Jeremy A. Rassen, Sebastian Schneeweiss, Dorothee B. Bartels
Publikováno v:
Clinical Epidemiology
Jeremy A Rassen,1 Dorothee B Bartels,2 Sebastian Schneeweiss,1,3,4 Amanda R Patrick,1 William Murk1,5 1Aetion, Inc, New York, NY, USA; 2BI X GmbH, Ingelheim, Germany; 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hosp
Autor:
Elizabeth M. Garry, Jeremy A. Rassen, Patrice Verpillat, Shirley V. Wang, Amanda R. Patrick, Dorothee B. Bartels
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:325-332
The scientific community and decision-makers are increasingly concerned about transparency and reproducibility of epidemiologic studies using longitudinal healthcare databases. We explored the extent to which published pharmacoepidemiologic studies u
Autor:
John D. Seeger, Elizabeth M. Garry, Olesya Zorina, Victoria G. Gillet, Dorothee B. Bartels, Sebastian Schneeweiss, Elisabetta Patorno, Amanda R. Patrick
Publikováno v:
Drug Safety. 38:295-310
A growing body of observational literature on the association between glucose-lowering treatments and all-cause mortality has been accumulating in recent years. However, many investigations present designs or analyses that inadequately address the me
Autor:
Keturah R. Faurot, M. Alan Brookhart, Michele Jonsson Funk, Laura C. Hanson, Amanda R. Patrick, Wendy Camelo Castillo, Til Stürmer, Virginia Pate
Publikováno v:
Pharmacoepidemiology and Drug Safety. 24:59-66
Purpose Estimating drug effectiveness and safety among older adults in population-based studies using administrative health care claims can be hampered by unmeasured confounding as a result of frailty. A claims-based algorithm that identifies patient
Publikováno v:
Journal of Bone and Mineral Research. 29:1667-1674
Fractures related to osteoporosis are associated with $20 billion in cost in the United States, with the majority of cost born by federal health-care programs, such as Medicare and Medicaid. Despite the proven fracture reduction benefits of several o
Autor:
Gregory W. Daniel, Rhonda L. Bohn, Joshua J. Gagne, Amanda R. Patrick, Niteesh K. Choudhry, Jun Liu, Sebastian Schneeweiss, Gayathri Sridhar, Jeremy A. Rassen
Publikováno v:
Drug Safety. 37:151-161
Methods for near-real-time monitoring of new drugs in electronic healthcare data are needed. In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routi
Autor:
Amanda R. Patrick, Elliot M. Antman, M.P.H. Troyen A. Brennan M.D., Kouta Ito, M.S.H.S. William H. Shrank M.D., Niteesh K. Choudhry, Jerry Avorn
Publikováno v:
Health Services Research. 47:2097-2117
Long-term adherence to secondary prevention medications after myocardial infarction (MI) is extremely poor (Choudhry et al. 2008a). For example, less than half of post-MI patients are adherent to their prescribed β-blocker or statin (Benner et al. 2